Neuroimaging offers a powerful strategy to chart the dynamic path of aging and Alzheimer's disease (AD) in the brain. This project will apply strategies with unprecedented sensitivity to detect, map, and analyze patterns of brain change (structural and functional) in AD and those at risk. Our novel brain maps will quantify disease progression to advance identification of early brain changes, and monitor treatment and gene effects. Using new mathematics and supercomputing technology, we will build on our work to create detailed 4D (dynamic) maps of brain changes based on serial magnetic resonance imaging (MRI). To increase sensitivity to detect and analyze drug and gene effects on brain changes, we will use (1) large cohorts scanned repeatedly over long intervals, and (2) improved image analyses using nonlinear deformation techniques and surface-based statistics. Algorithms will map the profiles, and rates, of cortical thinning, hippocampal change, gray matter loss, and volumetric atrophy. Collecting these maps from multiple populations, we will compare rates of brain change in patients with AD and FTD (Specific Aims 1 and 2), and MCI, CIND and healthy individuals with known risk genes (Aim 3). Probabilistic maps and statistics of these changes will be stored in a normative database, or brain atlas, and analyzed for group differences. We will stratify this population atlas by cohort, medication, symptom profiles, and risk genotype to help understand the dynamics of disease onset and progression, and how treatment affects these changes. We will determine how structural brain changes correlate with cognitive/metabolic decline (PET data) measured in the same subjects (Aim 4). In collaboration with an ongoing randomized, double-blind clinical trial (Aim 5), we will test whether drug treatment with donepezil and/or vitamin E decelerates atrophic rates in MCI subjects. The products of these efforts (engineering and neuroscience) will shed light on how dementia emerges in the brain and will improve our ability to track it. These tools will be publicly available, and will greatly expand our ability to investigate the dynamics of AD, detect its onset, compare patterns of therapeutic response, and understand its spatial/temporal selectivity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016570-09
Application #
7393171
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
9
Fiscal Year
2007
Total Cost
$232,372
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Cruchaga, Carlos; Del-Aguila, Jorge L; Saef, Benjamin et al. (2018) Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement 14:205-214
Joe, Elizabeth; Medina, Luis D; Ringman, John M et al. (2018) 1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. Brain Imaging Behav :
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340

Showing the most recent 10 out of 727 publications